Bernstein D, et al. - In this open-label, single-arm, Phase IIIa study, researchers examined patients with severe eosinophilic asthma (SEA) and their caregivers, to assess the usability of mepolizumab as a liquid drug product self-administered via a single-use prefilled autoinjector (AI) by SEA patients, or their caregivers, in-clinic and at home. For 12 weeks, mepolizumab (100 mg subcutaneously) was self-administered via an AI every 4 weeks by patients/caregivers. Investigator/site staff-determined proportion of patients who successfully self-administered their third and second doses were considered as primary and secondary endpoints, respectively. With no new safety issues, successful self-administration of mepolizumab via the AI by patients/caregivers, both in-clinic and at home, was reported in this study.